Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > Small molecules > regorafenib


Monday 5 March 2012

The small molecule regorafenib is an anti-VEGFR.

Regorafenib is a recently approved oral, multikinase inhibitor for refractory colorectal cancer.

Although structurally similar to sorafenib, it more potently inhibits a broader spectrum of critical growth receptor pathways, including those regulating angiogenesis and aberrant cellular proliferation.

See also

- http://www.targetedonc.com/publications/targeted-therapies-cancer/2013/August-2013/Regorafenib-in-the-Treatment-of-Colorectal-Cancer#sthash.MNPEI161.dpuf

- http://www.targetedonc.com/publications/targeted-therapies-cancer/2013/August-2013/Regorafenib-in-the-Treatment-of-Colorectal-Cancer